Interrupt or slow the rate of infusion or permanently discontinue Niktimvo based on severity of the reaction. Embryo-Fetal Toxicity Based on its mechanism of action, Niktimvo may cause fetal harm ...

1 “With the approval of Niktimvo, patients with chronic GVHD whose disease has progressed after prior therapies, now have a new treatment option with a novel mechanism of action to help address the ...

Interrupt or slow the rate of infusion or permanently discontinue Niktimvo based on severity of the reaction. Based on its mechanism of action, Niktimvo may cause fetal harm when administered to a ...

"With the approval of Niktimvo, patients with chronic GvHD, whose disease has progressed after prior therapies, now have a new treatment option with a novel mechanism of action to help address the ...

Interrupt or slow the rate of infusion or permanently discontinue Niktimvo based on severity of the reaction. Based on its mechanism of action, Niktimvo may cause fetal harm when administered to a ...

Reported adverse reactions for Niktimvo indicate a high occurrence of serious adverse reactions (44% of patients), including infections, which raises concerns about its safety profile. The trial's ...

now have a new treatment option with a novel mechanism of action to help address the serious and devastating complications associated with this disease," said Hervé Hoppenot, Chief Executive ...

Interrupt or slow the rate of infusion or permanently discontinue Niktimvo based on severity of the reaction. Embryo-Fetal Toxicity Based on its mechanism of action, Niktimvo may cause fetal harm ...

and Niktimvo™ (axatilimab-csfr) were accepted for presentation at the 30 th European Hematology Association (EHA) Annual Congress Meeting being held June 12-15, 2025, in Milan, Italy.

Niktimvo™ (axatilimab-csfr) is the first approved anti-CSF-1R antibody targeting the drivers of inflammation and fibrosis seen in chronic GVHD Pivotal data from the AGAVE-201 study supporting ...